Patients with resistant hypertension and hypokalemia are likely to have primary aldosteronism, which may be at the root of their condition. Screening rates patients for primary aldosteronism doesn’t appear to be common practice.
Several research studies presented at ENDO 2021 have evaluated the molecular mechanisms underlying Cushing syndrome to facilitate earlier diagnosis and improve disease management.
Cardiovascular disease is the leading cause of death in patients with adrenal insufficiency. In this study, UK researchers weighed the presence of comorbidities against cardiovascular morbidity and mortality.
The goal of this study was to evaluate 11-oxyandrogens in discriminating good vs poor disease control in 21OHD in the setting of discrepant 17OHP and A4.
Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism.
Hydrocortisone granules delivered accurate drug dosing to effectively treat pediatric adrenal insufficiency.
Osilodrostat treatment was found to be associated with a rapid and sustained reduction in mean concentration of urinary free cortisol and improved clinical symptoms in patients with Cushing’s disease.
Patients with Cushing syndrome are at an increased risk for infections, including severe COVID-19, due to immunodeficiency and other comorbidities.
High-resolution peripheral quantitative computed tomography can be used to assess bone abnormalities in patients with adrenal incidentaloma.
In patients with classical congenital adrenal hyperplasia, the use of modified-release hydrocortisone may improve biochemical control.
Primary aldosteronism is prevalent and increases in parallel with hypertension severity.